Fig. 4

Clinical significance of the positive correlation between BPTF and VEGF in evaluating the efficacy of bevacizumab in patients with lung adenocarcinoma. A total of 26 patients treated with bevacizumab were divided into two groups according to bevacizumab with good efficacy (sensitive) and poor efficacy (non-sensitive). a Immunohistochemistry was used to detect the expression level of BPTF between the two groups. Among them, three pairs of representative images were selected with 40X and 200X scales, respectively. b Immunohistochemistry was used to detect the expression level of VEGF between the two groups. Among them, three pairs of representative images were selected with 40X and 200X scales, respectively. c Expression of BPTF and VEGF in bevacizumab sensitive group and non-sensitive group. As shown in the chart: In the bevacizumab sensitive group, 12 cases had high expression of BPTF, and 5 cases had low expression. In the insensitive group, there were 2 cases with high expression of BPTF and 7 cases with low expression, P = 0.019 by Chi-square test, showing statistical difference. d VEGF expression was also detected in the two groups. The results showed that in the bevacizumab sensitive group, 11 cases had high VEGF expression and 4 cases had low VEGF expression; in the insensitive group, there were 6 cases of high VEGF expression and 5 cases of low VEGF expression. Although there was a higher VEGF expression trend in the bevacizumab sensitive group, the Chi-square test showed no statistical difference, P = 0.32